新辅助-话题@MedSci

#新辅助#

321篇内容 | 5135人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1678737, encodeId=d11e16e873723, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=AACR 2022：度伐利尤单抗和和曲美木单抗联合一线新辅助化疗治疗晚期卵巢癌患者的结果公布 (KGOG 3046/TRU-D), objectType=article, longId=724029, objectId=ae71e2402901, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae71e2402901, replyNumber=0, likeNumber=100, createdTime=2022-10-05, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae71e2402901, moduleTitle=AACR 2022：度伐利尤单抗和和曲美木单抗联合一线新辅助化疗治疗晚期卵巢癌患者的结果公布 (KGOG 3046/TRU-D), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae71e2402901)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678745, encodeId=23df16e874568, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=J Clin Oncol：新辅助化疗联合纳武单抗治疗可切除IIIA期非小细胞肺癌的3年预后, objectType=article, longId=727471, objectId=cd20e27471d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd20e27471d6, replyNumber=0, likeNumber=83, createdTime=2022-11-28, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd20e27471d6, moduleTitle=J Clin Oncol：新辅助化疗联合纳武单抗治疗可切除IIIA期非小细胞肺癌的3年预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd20e27471d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678741, encodeId=14ae16e8741e4, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=NEJM：纳武单抗+化疗作为可切除肺癌的新辅助治疗可大大改善患者预后, objectType=article, longId=724211, objectId=c373e242115e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c373e242115e, replyNumber=0, likeNumber=150, createdTime=2023-01-19, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c373e242115e, moduleTitle=NEJM：纳武单抗+化疗作为可切除肺癌的新辅助治疗可大大改善患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c373e242115e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678731, encodeId=fce116e873176, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Oncologist：局部进展期直肠癌(LARC)患者使用完全新辅助治疗(TNT)模式治疗并未能改善预后, objectType=article, longId=300702, objectId=67e2300e0251, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67e2300e0251, replyNumber=0, likeNumber=93, createdTime=2022-05-05, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67e2300e0251, moduleTitle=Oncologist：局部进展期直肠癌(LARC)患者使用完全新辅助治疗(TNT)模式治疗并未能改善预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67e2300e0251)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678711, encodeId=6eaa16e8711e8, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=BMC Cancer：双药对比三药新辅助治疗局部进展期胃癌(LAGC)的疗效：倾向评分匹配(PSM)研究, objectType=article, longId=291845, objectId=199829184512, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=199829184512, replyNumber=0, likeNumber=75, createdTime=2022-07-21, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=199829184512, moduleTitle=BMC Cancer：双药对比三药新辅助治疗局部进展期胃癌(LAGC)的疗效：倾向评分匹配(PSM)研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=199829184512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678755, encodeId=bf6116e8755f8, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=J Clin Oncol：阿特珠单抗联合新辅助化疗治疗HER2阳性早期乳腺癌, objectType=article, longId=731832, objectId=22efe318328a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22efe318328a, replyNumber=0, likeNumber=92, createdTime=2023-02-07, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22efe318328a, moduleTitle=J Clin Oncol：阿特珠单抗联合新辅助化疗治疗HER2阳性早期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22efe318328a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678716, encodeId=254616e87162d, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Front Oncol：回顾性研究比较白蛋白结合紫杉醇和多西他赛作为新辅助治疗治疗HER2-乳腺癌患者的疗效, objectType=article, longId=293860, objectId=16d129386032, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16d129386032, replyNumber=0, likeNumber=75, createdTime=2022-01-19, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16d129386032, moduleTitle=Front Oncol：回顾性研究比较白蛋白结合紫杉醇和多西他赛作为新辅助治疗治疗HER2-乳腺癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16d129386032)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678753, encodeId=a27916e87537d, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Ther Adv Med Oncol：洛铂新辅助治疗可改善三阴性乳腺癌患者预后, objectType=article, longId=731076, objectId=fee6e3107677, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fee6e3107677, replyNumber=0, likeNumber=87, createdTime=2023-04-11, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fee6e3107677, moduleTitle=Ther Adv Med Oncol：洛铂新辅助治疗可改善三阴性乳腺癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fee6e3107677)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678743, encodeId=2afa16e874379, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=卵巢癌新辅助化疗周期数的启示, objectType=article, longId=724865, objectId=f0fee2486581, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0fee2486581, replyNumber=0, likeNumber=92, createdTime=2022-07-17, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0fee2486581, moduleTitle=卵巢癌新辅助化疗周期数的启示, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0fee2486581)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678714, encodeId=0df416e87142c, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=BMC Cancer：对于局部晚期食管癌，如cT1N+和cT2Nany，新辅助治疗或辅助治疗更优？, objectType=article, longId=292998, objectId=6f1329299826, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f1329299826, replyNumber=0, likeNumber=77, createdTime=2022-02-24, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f1329299826, moduleTitle=BMC Cancer：对于局部晚期食管癌，如cT1N+和cT2Nany，新辅助治疗或辅助治疗更优？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f1329299826)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678752, encodeId=96d316e87522a, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Clin Cancer Res：局部晚期头颈部鳞状细胞癌的新辅助化疗+免疫治疗, objectType=article, longId=731133, objectId=8c55e311334c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c55e311334c, replyNumber=0, likeNumber=122, createdTime=2022-08-19, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c55e311334c, moduleTitle=Clin Cancer Res：局部晚期头颈部鳞状细胞癌的新辅助化疗+免疫治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c55e311334c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678763, encodeId=bdcc16e876335, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Luminal B型乳腺癌新辅助治疗策略, objectType=article, longId=736706, objectId=418fe36706b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=418fe36706b8, replyNumber=0, likeNumber=80, createdTime=2022-11-02, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=418fe36706b8, moduleTitle=Luminal B型乳腺癌新辅助治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=418fe36706b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678707, encodeId=5bc116e87079b, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=JAMA Oncol：局部晚期结直肠癌的全新辅助疗法——放化疗+诱导/巩固化疗！, objectType=article, longId=221421, objectId=c3fc22142171, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3fc22142171, replyNumber=0, likeNumber=87, createdTime=2022-04-09, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3fc22142171, moduleTitle=JAMA Oncol：局部晚期结直肠癌的全新辅助疗法——放化疗+诱导/巩固化疗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3fc22142171)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678744, encodeId=35a916e8744eb, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=BMC Med：阿帕替尼+奥沙利铂+卡培他滨新辅助治疗局部晚期胃癌/胃食管交界处癌, objectType=article, longId=726038, objectId=a34fe2603805, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a34fe2603805, replyNumber=0, likeNumber=102, createdTime=2023-01-30, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a34fe2603805, moduleTitle=BMC Med：阿帕替尼+奥沙利铂+卡培他滨新辅助治疗局部晚期胃癌/胃食管交界处癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a34fe2603805)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678699, encodeId=db5e16e8699f4, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Nat Med：新辅助T-VEC联合手术对可切除的IIIB-IVM1a期黑色素瘤患者的疗效分析, objectType=article, longId=218211, objectId=4e7c218211d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e7c218211d8, replyNumber=0, likeNumber=81, createdTime=2022-04-18, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e7c218211d8, moduleTitle=Nat Med：新辅助T-VEC联合手术对可切除的IIIB-IVM1a期黑色素瘤患者的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e7c218211d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678704, encodeId=628a16e870408, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Front Oncol：新辅助同步放化疗(nCRT)对可切除Siewert II型或III型胃食管交界处腺癌(AEG)的长期疗效影响, objectType=article, longId=220337, objectId=e64222033e7d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e64222033e7d, replyNumber=0, likeNumber=93, createdTime=2022-06-16, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e64222033e7d, moduleTitle=Front Oncol：新辅助同步放化疗(nCRT)对可切除Siewert II型或III型胃食管交界处腺癌(AEG)的长期疗效影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e64222033e7d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678700, encodeId=96f016e870095, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Cancers：早期乳腺癌患者新辅助放化疗的长期疗效和安全性, objectType=article, longId=218811, objectId=ff98218811b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff98218811b1, replyNumber=0, likeNumber=82, createdTime=2021-12-13, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff98218811b1, moduleTitle=Cancers：早期乳腺癌患者新辅助放化疗的长期疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff98218811b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678726, encodeId=943316e87269b, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效, objectType=article, longId=299451, objectId=fc31299451e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc31299451e9, replyNumber=0, likeNumber=80, createdTime=2022-07-01, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc31299451e9, moduleTitle=Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc31299451e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678724, encodeId=4eca16e872402, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Gastric Cancer: D1/D2和CRITICS研究事后探索可手术不同分子亚型胃癌对新辅助化疗的应答和预后, objectType=article, longId=299222, objectId=3b272992229b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b272992229b, replyNumber=0, likeNumber=101, createdTime=2022-06-22, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b272992229b, moduleTitle=Gastric Cancer: D1/D2和CRITICS研究事后探索可手术不同分子亚型胃癌对新辅助化疗的应答和预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b272992229b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678734, encodeId=5d7f16e87349f, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, objectTitle=Eur J Cancer：来曲唑+帕博西尼新辅助治疗或可替代高危型ER+HER2-乳腺癌的化疗, objectType=article, longId=301809, objectId=25d630180953, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25d630180953, replyNumber=0, likeNumber=89, createdTime=2022-11-26, rootId=0, userName=charl1234576, userId=941f27706894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25d630180953, moduleTitle=Eur J Cancer：来曲唑+帕博西尼新辅助治疗或可替代高危型ER+HER2-乳腺癌的化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25d630180953)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

新辅助

2020-05-29

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

AACR 2022：度伐利尤单抗和和曲美木单抗联合一线新辅助化疗治疗晚期卵巢癌患者的结果公布 (KGOG 3046/TRU-D)

2022-10-05

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

J Clin Oncol：新辅助化疗联合纳武单抗治疗可切除IIIA期非小细胞肺癌的3年预后

2022-11-28

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

NEJM：纳武单抗+化疗作为可切除肺癌的新辅助治疗可大大改善患者预后

2023-01-19

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Oncologist：局部进展期直肠癌(LARC)患者使用完全新辅助治疗(TNT)模式治疗并未能改善预后

2022-05-05

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

BMC Cancer：双药对比三药新辅助治疗局部进展期胃癌(LAGC)的疗效：倾向评分匹配(PSM)研究

2022-07-21

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

J Clin Oncol：阿特珠单抗联合新辅助化疗治疗HER2阳性早期乳腺癌

2023-02-07

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Front Oncol：回顾性研究比较白蛋白结合紫杉醇和多西他赛作为新辅助治疗治疗HER2-乳腺癌患者的疗效

2022-01-19

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Ther Adv Med Oncol：洛铂新辅助治疗可改善三阴性乳腺癌患者预后

2023-04-11

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

卵巢癌新辅助化疗周期数的启示

2022-07-17

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

BMC Cancer：对于局部晚期食管癌，如cT1N+和cT2Nany，新辅助治疗或辅助治疗更优？

2022-02-24

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Clin Cancer Res：局部晚期头颈部鳞状细胞癌的新辅助化疗+免疫治疗

2022-08-19

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Luminal B型乳腺癌新辅助治疗策略

2022-11-02

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

JAMA Oncol：局部晚期结直肠癌的全新辅助疗法——放化疗+诱导/巩固化疗！

2022-04-09

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

BMC Med：阿帕替尼+奥沙利铂+卡培他滨新辅助治疗局部晚期胃癌/胃食管交界处癌

2023-01-30

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Nat Med：新辅助T-VEC联合手术对可切除的IIIB-IVM1a期黑色素瘤患者的疗效分析

2022-04-18

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Front Oncol：新辅助同步放化疗(nCRT)对可切除Siewert II型或III型胃食管交界处腺癌(AEG)的长期疗效影响

2022-06-16

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Cancers：早期乳腺癌患者新辅助放化疗的长期疗效和安全性

2021-12-13

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Oncologist：Toripalimab（特瑞普利单抗）联合紫杉醇+卡铂新辅助治疗可切除局部晚期食管鳞状细胞癌的疗效

2022-07-01

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Gastric Cancer: D1/D2和CRITICS研究事后探索可手术不同分子亚型胃癌对新辅助化疗的应答和预后

2022-06-22

charl1234576 (审核中...)

前往app查看评论内容

#新辅助#

Eur J Cancer：来曲唑+帕博西尼新辅助治疗或可替代高危型ER+HER2-乳腺癌的化疗

2022-11-26

科室
- - 订阅+
  - 更多科室
工具
服务